STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Director at Neurocrine (NASDAQ: NBIX) converts 1,659 RSUs to shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neurocrine Biosciences director Gary A. Lyons exercised fully vested restricted stock units, converting 1,659 RSUs into the same number of common shares. This reflects a derivative exercise at a stated price of $0.00 per unit, typical for equity compensation.

After the transaction, Lyons directly holds 122,141 common shares, including 116,158 shares held through the Gary A. Lyons Revocable Living Trust, over which he has voting and investment power. The filing shows no share sales, only the RSU conversion into stock.

Positive

  • None.

Negative

  • None.
Insider LYONS GARY A
Role null
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,659 $0.00 --
Exercise Common Stock 1,659 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 122,141 shares (Direct, null)
Footnotes (1)
  1. 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.
RSUs exercised 1,659 shares Restricted Stock Units converted to common stock on May 21, 2026
Shares held after transaction 122,141 shares Total common stock directly held following RSU exercise
Trust-held shares 116,158 shares Common shares held by Gary A. Lyons Revocable Living Trust
Exercise price per RSU $0.00 per unit Stated conversion price for restricted stock units
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Revocable Living Trust financial
"held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12"
voting and investment power financial
"of which the Reporting Person has voting and investment power"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LYONS GARY A
(Last)(First)(Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026M1,659A$0122,141(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0(2)05/21/2026M1,659 (3) (3)Common Stock1,659$00D
Explanation of Responses:
1. 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power
2. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
3. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX director Gary A. Lyons report?

Gary A. Lyons reported exercising 1,659 restricted stock units into 1,659 common shares. This non-cash derivative exercise increased his direct equity holdings in Neurocrine Biosciences without any reported open-market share sales or dispositions in this filing.

How many Neurocrine Biosciences (NBIX) shares does Gary A. Lyons hold after this filing?

Following the RSU exercise, Gary A. Lyons holds 122,141 common shares. Of these, 116,158 shares are held in the Gary A. Lyons Revocable Living Trust, where he has voting and investment power, and the remainder is held directly in his own name.

Were any Neurocrine Biosciences (NBIX) shares sold in this Form 4 transaction?

No shares were sold in this Form 4. The reported activity is an exercise of 1,659 restricted stock units into common shares, with no accompanying sale, gift, tax withholding disposition, or other share disposition reported in the transaction summary.

What is the nature of the restricted stock units reported by NBIX director Lyons?

Each restricted stock unit represents the right to receive one Neurocrine Biosciences common share upon vesting. The RSU award reported here was granted on May 21, 2025 and is described as fully vested, enabling conversion into 1,659 common shares in this transaction.

How many RSUs did Gary A. Lyons have remaining after this NBIX Form 4?

After exercising 1,659 restricted stock units for common shares, the filing shows zero remaining RSUs from this award. The derivative summary is empty, indicating no additional derivative positions related to this specific reported RSU grant are outstanding in this Form 4.